Clinical Trial

CD70-targeted immunoPET Imaging of Malignant Cancers

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-24.
Trial Details
NCT Number NCT06852638
Lead Sponsor RenJi Hospital
Conditions Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma, Mantle Cell Lymphoma, Nasopharyngeal Carcinoma
Enrollment 300 participants
Start Date 2024-12-23
Primary Completion 2026-12-23 (estimated)
Study Completion 2026-12-23 (estimated)
Updated on ClinicalTrials.gov 2026-05-12